Alnylam Pharmaceuticals Profile

Performance

   

Odds of Distress

6%6%
Check how we calculate scores
Equity ratings for Alnylam Pharmaceuticals are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting June 24, 2019 and ending today September 22, 2019. Click here to learn more.

Alnylam Pharmaceuticals Summary

Alnylam Pharmaceuticals (ALNY) is traded on BATS Exchange in USA. It is located in 300 Third Street and employs 1,065 people. Alnylam Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 9.41B. Alnylam Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 111.21M outstanding shares of which 5.89M shares are presently shorted by private and institutional investors with about 7.64 trading days to cover. ALNYLAM PHARMACEU currently holds about 1.93B in cash with (402.69M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.33.
Check Alnylam Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Alnylam Pharmaceuticals Target Price Odds Analysis

Odds Below 84.6HorizonTargetOdds Above 84.6
91.15%30 days 84.60 8.77%
Based on normal probability distribution, the odds of Alnylam Pharmaceuticals to move above current price in 30 days from now is about 8.77% (This Alnylam Pharmaceuticals probability density function shows the probability of Alnylam Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Alnylam Pharmaceuticals Top Holders

Alnylam Pharmaceuticals Income Statement Over Time

Cost of Revenue    Earning Before Interest and Taxes USD    Gross Profit    

Alnylam Pharmaceuticals Key Fundamentals

Alnylam Pharmaceuticals Against Markets

Alnylam Pharmaceuticals Vital Trading Data

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 1065 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Alnylam Pharmaceuticals SEC Filings
Alnylam Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameAlnylam Pharmaceuticals
CEO, DirectorJohn MaraganoreView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationMassachusetts U.S.A
Business Address300 Third Street
ExchangeBATS Exchange
CIK Number0001178670
CUSIP02043Q107
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.alnylam.com
Phone617 551 8200
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestAugust 15, 2019

Current Sentiment - ALNY

Alnylam Pharmaceuticals Investor Sentiment

Most of Macroaxis users are presently bullish on Alnylam Pharmaceuticals. What is your sentiment towards investing in Alnylam Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Alnylam Pharmaceuticals Corporate Directors

Michael Bonney Director
Dennis Ausiello Independent Director
Phillip Sharp Independent Director
Check also Trending Equities. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Search macroaxis.com